Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezatapopt + Azacitidine in TP53Y220C Mutant AML or MDS
NCT06616636Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezatapopt in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
rezatapopt
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06616636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616636.